CANbridge Pharmaceuticals

Focus: CANbridge Pharmaceuticals is a China-based contract partner that localizes Western pharmaceutical assets for Asian markets, with a focused pipeline in neurology and rare diseases. Founded in 2012 and headquartered in Beijing, the company operates as a bridge entity connecting global pharma innovation to regional markets.

Neurology

Profile data last refreshed 1h ago · AI intelligence enriched 2w ago

Open Jobs

About CANbridge Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow CANbridge Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma

Glioblastoma

N/A

Clinical Trials (1)

NCT03152708CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma

N/A

Help build intelligence for CANbridge Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to emerging markets: positioned at the intersection of Western pharma and Asian market entry, offering exposure to high-growth regulatory and commercial landscapes.
Oncology and rare disease focus: pipeline concentrates on glioblastoma and hemolytic conditions with unmet needs, attracting mission-driven clinical and translational talent.
China biotech ecosystem: based in Beijing, offering immersion in one of the fastest-growing pharma innovation hubs with unique regulatory pathways.

Watch Out For

Early-stage pipeline maturity: all programs remain in Phase 1/2 with zero Phase 3 candidates, indicating minimal near-term commercial catalysts and revenue inflection risk.
No visible hiring: zero active job openings at time of assessment suggests limited growth or potential restructuring constraints.

Generated by Claude from CANbridge Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemoly

Paroxysmal Nocturnal Hemoglobinuria, Natural History Study

N/A

Clinical Trials (1)

NCT05125341Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemolysis in China

N/A

CAN008

Glioblastoma Multiforme

Phase 1

Clinical Trials (1)

NCT02853565A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme

Phase 1

CAN106

PNH

Phase 1

Clinical Trials (1)

NCT05095168Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects

Phase 1

Low-dose CAN103

Gaucher Disease, Type 1

Phase 1/2

Clinical Trials (1)

NCT05447494Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease

Phase 1/2

CAN106 20 mg/kg

PNH

Phase 1/2

Clinical Trials (1)

NCT05539248A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH

Phase 1/2

CAN008

GBM

Phase 2

Clinical Trials (1)

NCT03746288To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)

Phase 2

CAN008

Newly-diagnosed Glioblastoma

Phase 2

Clinical Trials (1)

NCT05447195Phase 2 Study of CAN008 in Subjects With GBM

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2012

Portfolio: 8 clinical trials

Top TAs: Oncology, Rare Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

3 pipeline

Rare Diseases

1 pipeline

Marketed

Pipeline

Visa Sponsorship

H-1B Petitions (FY2023)

Approved

Denied

Rate

Source: USCIS H-1B Employer Data Hub